Dr. Christopher Lipinski, Creator of ''Rule of Five,'' to Advise Medisyn Technologies on Pharmaceutical Industry Opportunities.MINNEAPOLIS -- Lipinski Joins Medisyn's Blue-Chip Scientific Advisory Board to Focus on High Profile Applications for Medisyn's Forward Engineering(TM) Technology Platform Medisyn Technologies, Inc. said today that Dr. Christopher Dr. John R. Christopher, known popularly as "Dr. Christopher" was one of very few nationally prominent doctors of herbal medicine of the middle third of the 20th century, a "dark ages" of herbalism and was responsible for the herbal renaissance of the 1960s. Lipinski--the world-renowned scientist and author of the pharmaceutical industry standard "Rule of Five" analysis--will join the Company as a Scientific Advisor and Consultant. Dr. Lipinski, who retired recently as Senior Research Fellow at Pfizer Global R&D, has been honored by the American Chemical Society The American Chemical Society (ACS) is a learned society (professional association) based in the United States that supports scientific inquiry in the field of chemistry. Founded in 1876 at New York University, the ACS currently has over 160,000 members at all degree-levels and in for his groundbreaking "Rule of Five" analysis. Since its publication in 1997, Lipinski's "Rule of Five" has emerged as a critical filter for drug development programs by helping to raise awareness about properties and structural features that make molecules more or less drug-like. A simple algorithm that helps to identify successful drug candidates, the "Rule-of-Five" is widely accepted within scientific circles as a landmark contribution to drug development. Currently, Dr. Lipinski serves as a scientific advisor to the Global Alliance for TB Drug Development, Melior Discovery, and the Matrical Company and is a consultant for the Hereditary HEREDITARY. That which is inherited. Disease Foundation. He also is a member of the editorial board of the Journal of Pharmaceutical Science and a winner of numerous scientific awards and professional citations. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Medisyn's president, David Land, "Since our first meeting, Chris has expressed a strong interest in Medisyn's technology and its potential to significantly improve drug discovery," Land said. "Our Board of Directors is delighted that Chris has agreed to work with Medisyn on specific projects that will showcase the exceptional capabilities of Medisyn's Forward Engineering platform," Land added. There is a significant, unmet un·met adj. Not satisfied or fulfilled: unmet demands. need for new drug lead candidates in the pharmaceutical industry. Currently, pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. are battling patent expirations and are struggling to improve drug development productivity which today is a costly and time-consuming process with no guaranteed success. Dr. Lipinski said he sees Medisyn's technology as potentially providing significant unrealized value to medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. in very important but historically challenging tasks such as the choice of the best chemical series for optimization against difficult targets. "I really hope that I can assist Medisyn in developing the retrospective "killer case histories" for the value of this technology in solving the historically very difficult medicinal chemistry problems posed by many of the really biologically exciting but chemically difficult new drug targets." About Medisyn Technologies Medisyn Technologies is a unique drug design and discovery company that uses proprietary technology to make drug discovery faster, more predictable and less expensive. Based on molecular topology topology, branch of mathematics, formerly known as analysis situs, that studies patterns of geometric figures involving position and relative position without regard to size. , Medisyn's Forward Engineering(TM) platform enables the discovery and design of novel, diverse and unexpected compounds that meet exact parameters for a specific therapeutic use. By compressing com·press tr.v. com·pressed, com·press·ing, com·press·es 1. To press together: compressed her lips. 2. To make more compact by or as if by pressing. 3. design and discovery time from years to weeks and optimizing lead candidates, Medisyn's novel approach enables drug discovery customers to reduce risk, improve probability of success and control costs associated with the traditional lead discovery process. The company is initially focused on treating cancer and is currently completing pre-clinical validation of MT103, a promising lead candidate for non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. . It has an additional 26 anti-cancer compounds in varying stages of development. Medisyn Technologies is headquartered in Minneapolis, MN. For more information about Medisyn Technologies, visit the company's website at: http://www.medisyntech.com or call 952.475.8084. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion